CVE-2024-26260

Hgiga OAKlouds - Command Injection

Description

The functionality for synchronization in HGiga OAKlouds' certain moudules has an OS Command Injection vulnerability, allowing remote attackers to inject system commands within specific request parameters. This enables the execution of arbitrary code on the remote server without permission.

Remediation

Solution:

  • Update OAKlouds-organization-2.0 to 188 or later version Update OAKlouds-organization-3.0 to 188 or later version Update OAKlouds-webbase-2.0 to 1051 or later version Update OAKlouds-webbase-3.0 to 1051 or later version

Category

9.8
CVSS
Severity: Critical
CVSS 3.1 •
EPSS 2.04% Top 20%
Third-Party Advisory org.tw Third-Party Advisory chtsecurity.com
Affected: Hgiga OAKlouds
Affected: Hgiga OAKlouds
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2024-26260?
CVE-2024-26260 has been scored as a critical severity vulnerability.
How to fix CVE-2024-26260?
To fix CVE-2024-26260: Update OAKlouds-organization-2.0 to 188 or later version Update OAKlouds-organization-3.0 to 188 or later version Update OAKlouds-webbase-2.0 to 1051 or later version Update OAKlouds-webbase-3.0 to 1051 or later version
Is CVE-2024-26260 being actively exploited in the wild?
It is possible that CVE-2024-26260 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~2% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-26260?
CVE-2024-26260 affects Hgiga OAKlouds, Hgiga OAKlouds.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.